StockNews.AI
APVO
StockNews.AI
152 days

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

1. 9 of 10 AML patients achieved remission with mipletamig treatment. 2. No CRS observed; cohort enrollment in RAINIER trial nears completion.

3m saved
Insight
Article

FAQ

Why Very Bullish?

The high remission rate of 90% signifies strong efficacy for mipletamig, boosting investor confidence. Historical examples show drug efficacy can lead to substantial stock price increases, e.g., with similar oncology therapies.

How important is it?

The strong clinical outcomes directly influence APVO's market perception and valuation. The lack of side effects and high remission rates elevate the potential of mipletamig, indicating future revenue growth.

Why Short Term?

The positive trial results can drive immediate investor interest and stock price growth. Previous biotech stock spikes have occurred swiftly following impactful trial data releases.

Related Companies

VRTXAZNBMY
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date Cohort 2 enrollment nears completion SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced two additional frontline AML patients have achieved remission* within 30 days of treatment in the Company's RAINIER dose optimization trial evaluating mipletamig in combination with standard of care for patients unfit for intensive chemotherapy. In total, 9 of 10 frontline patients across two trials achieved remission* when receiving the triplet combination of mipletamig + venetoclax + azacitidine (ven/aza).

Related News